doxifluridine + medroxyprogesterone acetate + mitoxantrone

This is a combination chemoendocrine therapy consisting of three agents: - **Doxifluridine** is an oral prodrug of 5-fluorouracil (5-FU), a fluoropyrimidine antimetabolite that inhibits DNA synthesis by interfering with thymidylate synthase after conversion to its active form in tumor cells. It is used as a cytostatic agent in chemotherapy and has demonstrated selectivity for tumor tissues expressing high levels of thymidine phosphorylase[9][6]. - **Medroxyprogesterone acetate** is a synthetic progestin hormone that exerts anti-tumor effects through hormonal modulation and may have direct antiproliferative activity on certain cancer cells. - **Mitoxantrone** is an anthracenedione antineoplastic agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of cell replication. This combination regimen has been studied primarily for the treatment of anthracycline-resistant advanced breast cancer. Clinical studies have shown moderate efficacy with manageable toxicity profiles in this setting[1][3][7]. The regimen leverages both cytotoxic (chemotherapy) and endocrine (hormonal) mechanisms to target resistant tumors.

Other names

doxifluridine5'-deoxy-5-fluorouridine5'-DFURmedroxyprogesterone acetateMPAmitoxantroneMIT